Thus, the protective effects of BCL2 inhibitors in AP are mediated, at least in part, by modulation of intracellular Ca2+ signaling – a mechanism also targeted by CRAC channel inhibitors [33–35]. The gene discussed is BCL2; the disease is alkaline phosphatase measurement.